Medical/Pharmaceuticals
Medit continues to see strong scanner adoption in Q1 2023
* Medit intraoral scanner installation is growing at almost 50% vs PY
* Medit Link serves as a key differentiator that has the potential to become
the cornerstone of digital dentistry SEOUL, South Korea and LONG BEACH, Calif.,
May 16, 2023 /PRNewswire/ -- Medit (www.medit.com
2023-05-16 08:00
3160
LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that the Phase II clinical trial of LNK01001 in the treatment of rheumatoid arthritis (RA) showed statistically signifi...
2023-05-16 08:00
3725
China International Medical Equipment Fair 2023 Held in Shanghai in May, Showcasing Cutting-Edge Healthcare Technologies
SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai. Hosted from May 14 – 17th, the show once again brought together the latest and the great solutions created to drive innovations and push th...
2023-05-15 22:56
3107
Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China
YANTAI, China, May 15, 2023 /PRNewswire/ -- Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company's Dulaglutide Injection (BA5101) inChina. BA5101 is a biosimilar of Trulicity®, used...
2023-05-15 21:58
3834
Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma
* Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC * HMBD-001 used as monotherapy and in combination with cetuximab has been ...
2023-05-15 18:30
2169
MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project
SHENZHEN, China, May 15, 2023 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, recently shared that a total of nearly 60,000 samples have been sequenced among 21 institutes and over 10 participating nations throughoutEurope, ...
2023-05-15 16:29
1846
BOTTICELLI, THE INQUIETUDE AND THE BEAUTY - Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance
FLORENCE, Italy, May 15, 2023 /PRNewswire/ -- Successful artist, sensitive interpreter of the culture of his time and author of extraordinarily relevant works, Sandro Botticelli was a master of beauty. With his "Venuses," he unknowingly established a canon of perfection that closely reflects tha...
2023-05-15 16:20
2031
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
DxI 9000 Access Immunoassay Analyzer Boasts Industry's Highest Throughput per Footprint: Up To 215 Tests/Hour/Square Meter Innovations Bolster Assay Performance and Laboratory Productivity with New Analyte Processing and Detection Technology, Precision Sensors, Smart Algorithms, Remote Real-Time...
2023-05-15 15:10
1704
TVM Capital Healthcare opens office in Riyadh, Saudi Arabia
DUBAI, UAE and RIYADH, Saudi Arabia, May 15, 2023 /PRNewswire/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announced today the opening of a new office in the capital of theKingdom of Saudi Arabia. The purpose of the new office is t...
2023-05-15 14:00
2893
Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis
SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases). The collaborat...
2023-05-15 12:30
2060
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-05-15 08:00
3280
Novarad's VisAR Receives FDA Clearance for Augmented Reality Surgical Navigation in Spinal Surgery in Indonesia
SALT LAKE CITY, May 13, 2023 /PRNewswire/ -- Novarad's VisAR, a surgical navigation system that uses augmented reality, has received clearance from Indonesia's FDA for intraoperative use in stereotactic spinal surgery. VisAR is accurate for both open and minimally invasive surgery (MISS). This cut...
2023-05-13 00:23
3402
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Heal...
2023-05-12 21:01
5262
CRM Trial Connect 2023: Minister of Health Malaysia, Dr. Zaliha Mustafa visits Taimei Technology's booth
SHANGHAI, May 12, 2023 /PRNewswire/ -- Taimei Technology, the digital platform for life science industry, attendedCRM Trial Connect 2023 held at the InterContinental Kuala Lumpur fromMay 11 to May 12, 2023. During the event, Dr. Zaliha Mustafa, Minister of Health Malaysia visited Taimei Technolog...
2023-05-12 19:36
3870
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023May 8;16(1):50). This study is the...
2023-05-12 17:40
2036
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, May 12, 2023 /PRNewswire/ -- An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the "Beijing Puhui Health Insurance Program." Nefecon is a first-in-disease treatment for adults with prim...
2023-05-12 07:40
3833
The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)
BARCELONA, Spain, May 11, 2023 /PRNewswire/ -- Esaote, one of the world's leading manufacturers of medical diagnostic systems (specifically, ultrasound, dedicated MRI and Medical IT systems) took part in the Congress held by the European Association of Cardiovascular Imaging inBarcelona on May 10...
2023-05-11 21:27
3302
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (Title: First-in-hum...
2023-05-11 20:55
2239
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
SAN DIEGO, May 11, 2023 /PRNewswire/ -- "Today we are pleased to announce that Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI ( Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one ...
2023-05-11 18:00
2331
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ -- In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable ...
2023-05-11 16:10
2683
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 292 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 254 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 250 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2937
